Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its financial results for the third quarter of 2024, highlighting significant advancements in its gene therapy programs and financial strategies. The …
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to host an in-person Clinical Showcase on Tuesday, November 12, 2024, at the Nasdaq MarketSite in Times Square, New York City, …
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the …
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy Read More MALVERN, PA — Dr. Shankar Musunuri, Chairman and CEO of Ocugen, Inc. (NASDAQ: OCGN), is set to join a panel discussion at the upcoming 2024 Maxim Healthcare Virtual Summit. Scheduled from …
Ocugen’s CEO to Present at 2024 Maxim Healthcare Virtual Summit Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a pivotal development as the FDA lifted the clinical hold on its investigational drug application for OCU200.
FDA Greenlights Ocugen’s Revolutionary Eye Treatment: What It Means for Vision Care Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will be participating in the 2024 Cell & Gene Meeting on the Mesa, scheduled for October 7-9 at the Arizona Biltmore in Phoenix, AZ. …
Ocugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the Mesa Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to participate in Chardan’s 8th Annual Genetic Medicines Conference in New York City.
Ocugen, Inc. to Feature at Chardan’s Genetic Medicines Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the 5th Annual Gene Therapy for Ophthalmic Disorders …
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will …
Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More